Advancing Brain Tissue and CNS Sample Handling and Distribution: Preserving Analytical Profiles of Central Nervous System (CNS) Samples for Neurodegenerative Disease Research Using Frozen Aliquotting Technology
A preview of this application note (paraphrased from the abstract):
As life expectancy continues to grow, it is widely expected that neurodegenerative disease will become a major healthcare burden. Investment in research on Alzheimer’s, Parkinson’s and other neurodegenerative diseases is essential to develop improved diagnostic and treatment options. Access to high quality annotated central nervous system (CNS) disease tissue is a significant bottleneck to progress in this area. Analysis of CNS samples can be challenging as both cerebrospinal fluid (CSF) and frozen brain tissue can be damaged with repeated freeze-thaw cycles, negatively impacting analytical outcomes. The use of frozen aliquotting technology (such as the CXT350) to acquire normalized amounts of tissue and frozen biofluids such as CSF can help reduce the impact of freeze-thaw damage to stored CNS biospecimens.
